Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3036% above fair value

$461.26−4.19 (-0.90%)

Close on Nov 3, 2026Market cap $249.37BP/E 28.6Yield 2.09%

Amgen KANJINTI (trastuzumab-anns by Year

Name: Amgen KANJINTI (trastuzumab-anns by Year (AMGN)
Creator: Amgen

KANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — Worldwide reported sales growth YoY (%) (%)

Quarterly Annual

Amgen KANJINTI (trastuzumab-anns: -50.0% in FY2023, down 5.0 pts from a year earlier. No newer figure appears in the documents we track.

Latest, FY2023

-50.0%

Period ended Dec 31, 2023

Change on a year earlier

-5.0 pts

-45.0% in FY2022

History

3 years

Since FY2021

Sources

Documents cited below

Where the FY2023 figure comes from

“|| KANJINTI ® | 109 | 50 | 159 | 316 | (50%)”

Source: Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗

Reported in Form 8-K Product Sales Detail by Product and Geographic Region.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	KANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — Worldwide reported sales growth YoY (%) (%)	Year on year	Source
FY2023	Dec 31, 2023	-50.0%	-5.0 pts	Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
FY2022	Dec 31, 2022	-45.0%	-46.0 pts	Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
FY2021	Dec 31, 2021	1.0%	–	Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗

Cite this data

StockData. (2026). Amgen KANJINTI (trastuzumab-anns (%), annual FY2021–FY2023 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-kanjinti-yoy

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.